PharmaLectures.com

Courses › Regulatory affairs by region › European Union: Novel excipients and the 2015 risk-assessment guideline, decoded

European Union: Novel excipients and the 2015 risk-assessment guideline, decoded

Your team stops losing months to excipient questions nobody prepared for.

  • 6 audio modulesthree lengths each
  • 1 h to 5 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • RA, QA, BDwho it is written for

Why this training matters

A launch is close to filing when someone finds an excipient nobody checked for novelty. Elsewhere, an inspector asks for the formalised risk assessment required under Article 46(f) of Directive 2001/83/EC and the file does not exist. Months go by while suppliers hunt for paperwork.

What changes after this course

Your team classifies each excipient early, runs the 2015 Guideline risk assessment and writes dossier sections that answer reviewers before they ask. You hold a certificate for every learner and a training record for each person.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory affairs manager looks at a new ingredient list and sorts it in minutes: established excipient, or novel under the European Medicines Agency excipient dossier guideline. No waiting for legal. The answer goes into the development plan before formulation is locked, so assessors do not come back with questions about missing safety or quality data.

A quality assurance specialist opens a new file and writes the formalised risk assessment that Article 46(f) of Directive 2001/83/EC and the 2015 Guideline call for. Source, function, quantity in the product and patient exposure are already answered, because the supplier questions were asked at the start, not the week before the audit.

When a supplier changes a production method, the email no longer starts a scramble. Your team checks whether it is a variation under Regulation (EC) No 1234/2008, reopens the risk assessment, updates the Module 3 section and records the decision. The batch schedule holds.

In the inspection room, the question about a binder gets an answer from a prepared file. Your site shows how it ascertained appropriate Good Manufacturing Practice, who decided, and when the assessment was last reviewed. Nobody improvises, and the inspector has what they came for.

Who needs this training

  • Regulatory Affairs Manager

    You open a draft Module 3 and cannot tell whether the excipient data matches the risk assessment. Afterwards you check one against the other before the dossier goes to the assessing authority, such as the European Medicines Agency.

  • Quality Assurance Specialist

    An inspector asks for the risk assessment on a new binder. You hand over a file that links the supplier's answers to the controls you chose, with the date and the person who decided.

  • Business Development Lead

    You are weighing a product acquisition and spot an unfamiliar excipient in the dossier. You can estimate the regulatory work and the delay it adds before the deal is signed.

Roles: Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Classify an ingredient as novel or established before formulation is locked, using the European Medicines Agency excipient dossier guideline.
  2. Write a formalised risk assessment that follows the 2015 Guideline and cites Article 46(f) of Directive 2001/83/EC.
  3. Request the origin, manufacturing and traceability details you need from an excipient supplier, in writing.
  4. Decide whether a supplier's process change needs a variation under Regulation (EC) No 1234/2008 and when to reopen the risk assessment.
  5. Lay out the excipient section of Module 3 so a reviewer finds each answer without writing back.
  6. Answer an inspector's questions on excipient Good Manufacturing Practice from a prepared file.

What the company gets

  • Novel excipients are caught before formulation is locked, so filings stop slipping over missing safety or quality data.
  • Every excipient has a dated, formalised risk assessment on file that an inspector can read from start to finish.
  • Supplier data is requested early and in writing, so audit week is no longer spent chasing paperwork.
  • Each learner has a certificate and a training record, so you can show who was trained on Directive 2001/83/EC and the 2015 Guideline.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 6 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard2 h 30 min25 min a module, for regulatory, quality and business-development staff
Expanded5 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Business development and export salesBriefing1 h
Regulatory affairsStandard2 h 30 min
Quality assurance and Qualified PersonStandard2 h 30 min

Course outline: 6 modules

6 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Apply Directive 2001/83/EC to every excipient in your supply chain

    • Why Article 46(f) of Directive 2001/83/EC makes the excipient check your site's job, not the supplier's.
    • How to sort your excipient list so the risky materials get attention first and the rest do not.
    • What to do when a supplier says the excipient is pharmaceutical grade and sends nothing else.
  2. 2Catch novel excipients before they stall your European filings

    • How to tell whether an excipient is novel before formulation is locked and the timeline is set.
    • Why a first-time route of administration can make a familiar excipient novel.
    • What to do when a supplier swaps in an undocumented excipient after your formulation is set.
  3. 3Run the 2015 Guideline formalised risk assessment on any excipient

    • How to build the formalised risk assessment file an inspector can follow from excipient to conclusion.
    • The risk factors in the 2015 Guideline that decide whether an excipient needs light or heavy controls.
    • When a supplier questionnaire is enough and when you must audit the supplier site.
  4. 4Draft excipient dossier sections reviewers can read in one pass

    • How to lay out the excipient section of Module 3 so the reviewer finds each answer where expected.
    • The traceability records your quality team pulls together before the dossier leaves the building.
    • What to ask the supplier for in writing so the gaps close before the reviewer finds them.
  5. 5Handle excipient manufacturing changes without a rejected batch

    • How to tell which excipient changes need a variation under Regulation (EC) No 1234/2008.
    • What to do the day a supplier reports a deviation, before the affected batch is rejected.
    • When a supplier's new production method means reopening your formalised risk assessment.
  6. 6Answer inspector questions on excipient Good Manufacturing Practice

    • The first excipient files an inspector asks to see, and how to have them on the table.
    • How to rehearse answers to the usual excipient questions so no one improvises in the room.
    • The short list of records that shows your site ascertained appropriate Good Manufacturing Practice.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

6 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h in the briefing length and 5 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for RA, QA, BD. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 54 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team